10 facts on Therma Bright
1) THRM’s CEO got a bonus. It’s done! Move on…it’s now a sunk cost, regardless what you think.
2). THRM shareholders didn’t vote Board out at last AGM.
3) THRM had little sales revenue per Q3 MD&A (period end April 30) posted in June 2022 SEDAR.com. Not a big deal for TSX.v’s. No $$ on AcuVid, InterceptCS, TheroZap, and little $ on Venowave and Benepod.
4) THRM’s Venowave units shipped to DME. Anticipated sale revenue $ in Q4/ FY2022 (due on Nov 30 for TSX.v -120 days post year close)
5) THRM’s AcuVid’s U.S. Clinical Study exceeding FDA and HC minimum requirements [minimums PPA 80.0% / NPA 96.0%, RT PCR CT levels, cross reactivity, interference, variant and 95% CI ]
6) THRM submitted FDA EUA and HC IO#3 applications in June 2022. & engaging with FDA & HC on AcuVid application reviews - Q&A phase.
7) THRM’s AcuVid 80.3%+ PPA beats at least 1 test - Ortho PPA 80.0% - had FDA EUA.
8). THRM’s Acuvid U.S. Study tested approx 230 people, Ortho had 105, Ellume (81.8% PPA) had 89 people, Access Bio 92 people , Quorvo Omnia 89 people, NANO-DITECH 76 people. All granted FDA EUA 2021-2022.
9) 99% of THRMs shares being held tightly. About 1% traded over past 2 weeks, excluding TSX Market Makers fluidity requirements.
10). THRM didn’t make you invest in company. You ownthat!
Welcome to the facts… I challenge you to argue against any of them..